The Journal of Thoracic and Cardiovascular Surgery
Volume 139, Issue 2 , Pages 474-482, February 2010

Adenosine A2A receptor activation on CD4+ T lymphocytes and neutrophils attenuates lung ischemia–reperfusion injury

  • Ashish K. Sharma, MBBS

      Affiliations

    • Department of Surgery, University of Virginia Health System, Charlottesville, Va
  • ,
  • Victor E. Laubach, PhD

      Affiliations

    • Department of Surgery, University of Virginia Health System, Charlottesville, Va
    • Corresponding Author InformationAddress for reprints: Victor E. Laubach, PhD, University of Virginia Health System Department of Surgery, PO Box 801359, Charlottesville, VA 22908.
  • ,
  • Susan I. Ramos

      Affiliations

    • Department of Medicine, University of Virginia Health System, Charlottesville, Va
  • ,
  • Yunge Zhao, MD, PhD

      Affiliations

    • Department of Surgery, University of Virginia Health System, Charlottesville, Va
  • ,
  • George Stukenborg, PhD

      Affiliations

    • Department of Public Health Sciences, University of Virginia Health System, Charlottesville, Va
  • ,
  • Joel Linden, PhD

      Affiliations

    • Department of Medicine, University of Virginia Health System, Charlottesville, Va
  • ,
  • Irving L. Kron, MD

      Affiliations

    • Department of Surgery, University of Virginia Health System, Charlottesville, Va
  • ,
  • Zequan Yang, MD, PhD

      Affiliations

    • Department of Surgery, University of Virginia Health System, Charlottesville, Va

Received 3 April 2009; received in revised form 15 June 2009; accepted 9 August 2009. published online 12 November 2009.

Objective

Adenosine A2A receptor activation potently attenuates lung ischemia–reperfusion injury. This study tests the hypothesis that adenosine A2A receptor activation attenuates ischemia–reperfusion injury by inhibiting CD4+ T cell activation and subsequent neutrophil infiltration.

Methods

An in vivo model of lung ischemia–reperfusion injury was used. C57BL/6 mice were assigned to either sham group (left thoracotomy) or 7 study groups that underwent ischemia–reperfusion (1 hour of left hilar occlusion plus 2 hours of reperfusion). ATL313, a selective adenosine A2A receptor agonist, was administered 5 minutes before reperfusion with or without antibody depletion of neutrophils or CD4+ T cells. After reperfusion, the following was measured: pulmonary function using an isolated, buffer-perfused lung system, T cell infiltration by immunohistochemistry, myeloperoxidase and proinflammatory cytokine/chemokine levels in bronchoalveolar lavage fluid, lung wet/dry weight, and microvascular permeability.

Results

ATL313 significantly improved pulmonary function and reduced edema and microvascular permeability after ischemia–reperfusion compared with control. Immunohistochemistry and myeloperoxidase content demonstrated significantly reduced infiltration of neutrophils and CD4+ T cells after ischemia–reperfusion in ATL313-treated mice. Although CD4+ T cell–depleted and neutrophil-depleted mice displayed significantly reduced lung injury, no additional protection occurred when ATL313 was administered to these mice. Expression of tumor necrosis factor-α, interleukin 17, KC, monocyte chemotactic protein-1, macrophage inflammatory protein-1, and RANTES were significantly reduced in neutrophil- and CD4+ T cell–depleted mice and reduced further by ATL313 only in neutrophil-depleted mice.

Conclusions

These results demonstrate that CD4+ T cells play a key role in mediating lung inflammation after ischemia–reperfusion. ATL313 likely exerts its protective effect largely through activation of adenosine A2A receptors on CD4+ T cells and neutrophils.

CTSNet classification: 12, 38.1

Abbreviations and Acronyms: A2AAR, adenosine A2A receptor, BAL, bronchoalveolar lavage, IgG, immunoglobulin G, IL-17, interleukin-17, IR, ischemia–reperfusion, LV, left ventricular, MCP, monocyte chemotactic protein, MIP, macrophage inflammatory protein, MPO, myeloperoxidase, RANTES, regulated on activation, normal T expressed and secreted, TNF-α, tumor necrosis factor-alpha, WBC, white blood cell

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Disclosures: Drs Linden and Kron were shareholders in Adenosine Therapeutics, LLC, the corporation that provided ATL313, during the time of this study.

 This study was funded by NIH/NHLBI grants RO1 HL077301 (to V.E.L.) and PO1 HL073361 (to J.L.).

PII: S0022-5223(09)01085-X

doi:10.1016/j.jtcvs.2009.08.033

The Journal of Thoracic and Cardiovascular Surgery
Volume 139, Issue 2 , Pages 474-482, February 2010